Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology's stages.

In this present work we provide arguments that support the hypothesis that there is a lack of integration between academia and industry to finance and continue research, especially the development of clinical studies. We cite the translational research consortia as the potential alternative for developing DDSs to combat NTDs.